Moshe Mizrahy: One more thing I wanted to add here, which is important, and at the end of the day we’re in a static company. So, every platform, including envision, will have some hand pieces to do aesthetic. So, the ophthalmologist can do periobital wrinkles with more views. You can do skin tightening or full [indiscernible], which are approved indication by the FDA. So, for him, he has one modality to do dry eye, and two or three more modalities on the same platform to get more money from the customers, private money on, skin rejuvenation, full of face rejuvenation, periobital wrinkles etcetera. And the end of the day, it’s a money machine.
Mike Matson: Yeah, understand. And then just one of the things he called out in terms of increased sales marketing spending was DTC, how did you see a campaign, I guess. So, can you maybe just talk about that kind of where you’re sending? Is it kind of social media, is it, so liberty, endorsement is it, I don’t think you’re doing the TV advertising, but maybe I missed that.
Moshe Mizrahy: Everywhere, everywhere. All the way from Billboard, to social media, website, B2B, B2C meetings with doctors, seminars, conferences, doctor conferences, study publication, everything.
Mike Matson: No TV advertising.
Shakil Lakhani: We typically choose to diversify what we do these things, and then we get a metric based on where we try and attempt to track what’s being successful and where money is not being spent the right way, and then we double down in areas where we’re seeing a good return.
Moshe Mizrahy: And we do have random back to those ones
Mike Matson: All right. Okay.
Operator: The next question is from Ryan Barokas with SVB Securities. Please go ahead.
Ryan Barocas: Hey, this is Ryan Barokas from UBS on for Danielle today. Thanks for taking our questions. So first one from us here is on capital allocation. So congrats on the recent acquisitions of IV patents. Just wanted to get an update on your capital allocation priorities as a whole. Is your appetite still as high as it’s been in recent quarters despite these patent acquisitions and can we expect more IP and smaller type deals or is it still possible? We see a larger size deal in the near future.
Moshe Mizrahy: Well, I would say two things. One, if the opportunity will present itself to buy more IP which relates to our business and enhance our IP portfolio position, we will do it. We did one license with the University of California on something which also relate to women health. We bought the entire portfolio of [indiscernible] not for big money. So, it’s not something that we need tens of million of dollars. We will not — we will not spend that kind. Now regarding capital allocation, we are exploring all the time M&A opportunities. We are currently working with few banks. None of them exclusive, none of them exclusive. We open it to every bank who can come up with something. We do a quick check and if something looks okay to us, we will we will continue to search and explore and do some diligence. I cannot report on something that will happen in the next month or two, but this is the plan.
Ryan Barocas: Great. Thanks, Moshe and then one last one for me on the capital environment and potential upgrades for new technology for your customers. So we’ve heard from other capital intensive companies highlight a higher mix of leasing as a percent of their system placements. Just curious if you’re seeing the same dynamic and then with the new technologies for your customers on these leasing arrangements, are there technology obsolescence clauses that would allow customers to upgrade to your new technology over the next 12 months? Or would this just be a simple software update on existing systems in the field for customers to access this new technology? Thanks so much.
